Clinical trials
Follicular Lymphoma clinical trials
Below are recruiting follicular lymphoma clinical trials, each written for real people, not researchers. We’re tracking 156 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07293403RecruitingPhase 2
Duvelisib maintenance for peripheral T-cell lymphoma
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Scottsdale, ArizonaAges 18 years+ - NCT06522737RecruitingPhase 3
Duvelisib vs chemotherapy for relapsed T-cell lymphoma
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
GhentAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT06947967RecruitingPhase 3
Tucidinostat plus CHOP for newly diagnosed PTCL-TFH lymphoma
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–80 - NCT05230680RecruitingPhase 1/Phase 2
Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
SeoulAges 20–85 - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT05899621Recruiting
Study of obinutuzumab-based treatment for untreated follicular lymphoma
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06959732RecruitingPhase 2
Zanubrutinib with G-CVP for untreated follicular lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for follicular lymphoma?
- Yes. Clin2 currently lists 156 recruiting follicular lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a follicular lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a follicular lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.